Immune Tolerance in Transplantation

For people who receive an organ transplant, immunosuppressive drugs are a lifeline that prevents their immune system from rejecting the transplant. However, these drugs work by suppressing all of the immune system - even the parts that protect from real threats. This means that people taking immunosuppressive drugs are at risk of developing serious infections.

The Immune Tolerance Network (ITN) is working to find new therapies that reprogram the immune system in a way that will allow people to maintain the health of the organ without long-term use of immunosuppression, also known as tolerance. 

           Kidney Transplant Trials                                  Liver Transplant Trials                  
                                                                        

This section contains a list of ITN's transplantation clinical trials that are currently enrolling participants. To see all of ITN's active and completed studies in transplantation, please visit For Researchers.

Clinical Trials - Transplantation

Allograft Tolerance Study (ALLTOL)

Principal Investigator:
Laurence Turka, MD, Massachusettes General Hospital, Boston, MA

ALLTOL is an observational clinical study to learn more about tolerance in organ transplantation.

Learn more:

Evaluation of Donor Specific Immune Senescence and Exhaustion as Biomarkers of Tolerance Post Liver Transplantation (OPTIMAL)

Principal Investigator:
James Markmann, MD, PhD, Massachusettes General Hospital, Boston, MA

OPTIMAL is a clinical trial that will be investigating immunosuppression withdrawal in liver transplant recipients.

Learn more: